Toulon on the Mediterranean sea, October 11 to 14, 1989. Seventy participants enjoyed a very stimulating series of lectures and discussion sessions dealing with the topics of immunology (T cell receptor, MHC antigen interaction, immunoregulation, cytokines) and immuno-nephrology (cytokines and lymphocyte activation in uremic and hemodialyzed patients, phenotype, repertoire and function of cells infiltrating renal ailografts, aberrant expression of MHC antigen in autoimmune lupus and diabetes, idiotype network in systemic lupus and interstitial nephritis, monoclonal anti-T cell antibodies, etc.).
Interstingly, in the spirit of ISN Forefront Symposia, the attendance included an equilibrated balance of nephrologists, immunonephrologists, and immunogists. Several major points emerged, notably the importance of studying the B and T cell repertoire in autoimmune and allogeneic reactions, as well as the interest of new explanations for lymphocyte disturbances observed in hemodialyzed patients, which could probably lead to a final understanding of the onset of amyloidosis in such patients and hopes for more selective and specific immunointervention.
All participants agreed that, in addition to the new information provided, the meeting illustrated the liveliness of the immunological approach in nephrology and the need for future meetings of this type. They were all grateful to ISN to have permitted such an opportunity.
T cell receptor The elucidation of the nature and of the genetic organization of the T cell receptor opened new perspectives in the study of cell-mediated immunity. Two lectures, by T. Mak (Toronto) and B. Malissen (Marseille), provided a unique update on the two types of T cell receptor: the c43 and the y.5 heterodimers.
Particular emphasis was made on the respective functions of the two receptor types. Arguments were presented suggesting that the yb receptor is used early in ontogenesis and may exert a regulatory function on af3+ T cells.
The TCR repertoire of T cells infiltrating renal allografts was discussed by J.P. Soulillou (Nantes). Cells were recovered from rejected kidneys and grown in culture in the presence of interleukin 2. No obvious bias in the T cell repertoire was evidenced. One may assume, however, that the situation is Received for publication May 7, 1990 © 1990 by the International Society of Nephrology different at the initiation of rejection where a more restricted T cell response operates. The observation made in several autoimmune diseases and some alloimmune responses that selected V/3 genes are used suggest the possible restriction of V gene usage by alloreactive T cells. It is indeed a crucial problem to know whether T cells use a single or a limited number of V genes in allograft rejection or autoimmune diseases, as they have been shown to do in experimental allergic encephalomyelitis and in the response to some defined antigens. It is important on a theoretical basis. It could also be important from a therapeutic viewpoint, with the potential use of selective anti-V13 monoclonal antibodies permitting an avoidance of the over-immunosuppressive states often observed with anti-pan T cell antibodies.
Regulatory T cells. Role in diabetes, interstitial nephritis and mercury-induced membranous nephropathy
The existence of suppressor T cells has recently been questioned. This denial is based on the absence in the major In the same vein, P. Druet (Paris) described an interesting model of immune dysregulation induced by mercury chloride injections in the BN rat. This treatment leads to the onset of membranous nephropathy. Arguments have been collected to indicate that the autoimmune response against tubular antigens as well as the immune complex deposition that are characteristic of this experimental nephritis are secondary to polyclonal B cell activation by mercury.
Aberrant expression of MHC products in autoimmunity
The nature of the triggering events that lead to autoimmunity is still essentially unknown. A current hypothesis holds that autoantigens may become immunogenic when they are associated with aberrantly increased expression of class II MHC products by the autoantigen bearing cells. Such aberrant expression of MHC antigens has indeed been observed in several human autoimmune diseases: Graves' disease, type I diabetes, primary biliary cirrhosis, etc. The problem remains, however, to determine whether this aberrant expression of MHC antigens is primary (induces the immune response) or secondary (to the immune response elicited by other mechanisms). A lively discussion took place on this central topic of autoimmunity.
The "inventor" of the theory, F. Bottazzo (London) presented several arguments in favor of a primary role, notably the consistency of aberrant MHC class II expression in early stages of several autoimmune diseases, and in vitro induction of this aberrant expression by cytokines (IFNy and TNFa).
He was challenged by C. Benoist (Strasbourg) who described experiments in which mice made transgenic for 13 cell-directed MHC antigens (class II) did not show diabetes, a finding suggesting that aberrant MHC expression on f3 cells even during fetal development is not sufficient to induce autoimmunity.
Additionally, V. Kelley (Boston) reported the aberrant class II and increased class I MHC antigen expression in the kidneys of lupus mice, without chosing, however, between the primary and secondary nature of these observations. Cytokines in hemodialyzed patients C. Dinarello (Boston) discussed the influence of dialysis on interleukin 1 production by human mononuclear cells.
There is ample clinical evidence supporting the contribution of IL-l in hemodialysis (HD)-induced pathology; several factors could be responsible for abnormal IL-i production, namely dialysis membrane monocyte interaction, presence of bacterial pyrogen in the dialysate, and serum factors such as complement components which are generated during HD treatment. Data were shown indicating that significant IL-I activity can be detected in the plasma on long-term HD patients treated with regenerated cellulosic membranes.
In vitro, it was also shown that regenerated cellulose (RC) and polyacrilonitrile (PAN) membrane can induce IL-1 production by human mononuclear cells (MNC) in the absence of endotoxin and complement. The PAN membrane induces significantly more IL-i than the RC, but this may be masked by the fact that PAN binds IL-i. In a closed-loop dialysis circuit, in the presence of plasma, IL-i induces various factors to pass into the blood compartment of a dialysis system challenged with bacterial pyrogen. This in vitro MNC-IL-l production provides a reliable and relevant assay to determine dialysis membrane permeability under the influence of pyrogens. In vitro addition of indomethacin to MNC cultures of normal subjects without medication increases IL-l/3 production. In vivo production of IL-lJ3 is significantly increased in normal volunteers given a cyclo-oxygenase inhibitor (aspirin, ibuprofen or Naproxen) during the previous week as compared to subjects without medication. When MNC from both groups were stimulated in the presence of indomethacin, the production of IL-i was increased in the group without medication, but was statistically unchanged in the group taking cyclooxygenase inhibitors. Lastly, C. Dinarello presented conclusive evidence showing that lipid A is the main portion of LPS responsible for induction of both extracellular and cell-associated IL-i, and that specific activation and/or binding mechanisms are involved in stimulation of cells with LPS and lipid A.
B. Descamps-Latscha (Paris) presented results obtained in the study of the respective influence of uremia and hemodialysis (HD) on circulating IL-i and TNFa. IL-l and TNFa were determined in the plasma of long-term hemodialysis (HD) patients and uremia (UR) patients undergoing their first dialysis session using either cuprophan or PAN membrane equipped dialyzers. In long-term HD patients, plasma IL-i and TNFa levels were significantly increased compared to their levels in normal subjects. During a single dialysis session, a significant increase in IL-i but not in TNFa was observed.
In not yet dialyzed UR patients, IL-i plasma levels did not differ from those observed in normal subjects. By contrast, TNFa was found significantly increased although less than in long-term HD patients. During the first dialysis session, no significant increase was observed in the levels of either monokine. Lastly, regardless of the group of patients, no significant influence of the dialysis membrane could be detected, suggesting that the observed changes are not exclusively secondary to the activation of complement. All together, these results suggest that the passage of the blood through the extracorporeal dialysis circuit triggers the secretion of IL-i and further exacerbates that of TNFa by monocytes. The presence of increased TNFa in the plasma of first dialysis UR patients suggests that factors unrelated to dialysis contribute to the activation of monocytes in these patients. Lastly, the concomitant presence of IL-l and TNFa in the plasma of long-term HD patients could be responsible for some of the clinical features observed in these patients, and provides strong evidence favoring the concept that HD can be assimilated to a recurrent acute-phase inflammatory response. S. Meuer (Zurich) presented evidence of a selective blockade of the antigen-receptor mediated pathway of T cell activation in patients showing unpaired primary immune responses secondary to chronic renal failure.
Unresponsiveness to hepatitis B vaccine correlates with a blockade of the 13-Ti antigen receptor-mediated mode ofT cell activation, whereas the Ti 1 pathway remains unaffected. Reduced I cell activity is a consequence of monocyte failure.
Monocyte function with regard to T cell receptor activation is not restricted to insufficient IL-i production but also involves the subsequent failure to produce IL-2. This view is supported by the demonstration that addition of IL-2 fully reconstituted the abnormal proliferative responses of non-responder lymphocytes after antigen-receptor triggering. Based on these observations, S. Meuer suggested that addition of IL-2 during vaccination may represent a useful strategy to circumvent the non-responder state in vivo in hemodialyzed subjects and perhaps improve the overall immunodeficiency known to exist in patients with chronic renal failure.
The therapeutic use of monoclonal antibodies and cytokines H. Waldmann (Cambridge) discussed the in vivo use of murine and humanized monoclonal anti-T cell antibodies. Anti-CD4 antibodies can promote the induction of tolerance towards transplantation antigens. There is no requirement for CD8 cells for the generation of tolerance, nor is there any evidence of transferable suppression. Tolerance can be maintained indefinitely if the antigen is reinjected every five weeks without further need for anti-CD4 MoAb therapy, the so-called "reinforcement phenomenon." Importantly, there is no need for depletion of CD4+ cells to induce the tolerance. Similar data were reported for a non-depleting MoAb to another T cell surface adhesion molecule LFA-l. Lastly, tolerance may be induced towards minor histocompatibility antigens (Mls). Tolerance is best achieved when one associates anti-CD4 and anti-CD8 MoAbs or their F(ab')2 fragments (which do not induce any cellular depletion). H. Waldmann also discussed the important issue of humanized MoAbs, especially of CAM-PATH-lH, a genetically reshaped human IgGI monoclonal antibody. CAMPATH-l is an IgGl directed towards an antigen abundantly expressed on virtually all lymphoid cells and monocytes, but not on other cell types. The IgG2b rat CAMPATH-1G is the most actively depleting anti-T cell MoAb in vivo, probably because it binds to human Fc receptors and activates complement. CAMPATH-1G is very effective in the treatment of lymphoid malignant disorders. Unfortunately, its use is hampered by the rapid occurrence of a neutralizing antiglobulin response. In order to circumvent this major side effect, a reshaped CAMPATH-1H obtained by molecular engineering was constructed. This MoAb associates the hypervariable regions of the rat antibody with normal human immunoglobulin constant region. The chimeric antibody still exhibits the same T cell depleting and complement activation properties of the rat antibody. Four patients suffering from either non-Hodgkin lymphomas or from severe autoimmune diseases (rheumatoid arthritis) were treated with the antibody. Results show that in addition to being apparently effective in treating the disease, the MoAb did not induce any serologically detectable antibodies. The results are encouraging but remain to be confirmed. Finally, H. Waldmann presented very recent data dealing with the effect of graft perfusion with two rat anti-human CD45 monoclonal antibodies (anti-pan leucocytes) on the incidence of kidney allograft rejection. Seventy-seven patients were randomized to receive first cadaver kidney allografts perfused either with a pair of CD4S monoclonal antibodies in an attempt to reduce the immunogenicity of passenger leucocytes (that are potent antigen presenting cells) or with human albumin solution. Patient and allograft survivals were similar in both groups, but, rejection episodes were recorded in 18% of the patients treated with the MoAbs, whereas 63% of the albumin perfused kidneys experienced rejection episodes.
L. Chatenoud (Paris) discussed the in vivo immunologic effect of anti-T cell receptor (CD3/Ti) antibodies in human renal allograft recipients. OKT3, a murine anti-human CD3 monoclonal antibody is one of the most potent and widely used immunosuppressive agent in organ transplantation. One major side effect associated with the in vivo use of OKT3 is the spontaneously reversible, systemic clinical reaction that invariably follows the first injections of this MoAb. This systemic reaction mainly includes chills, headache, pyrexia, vomiting, diarrhea, tachycardia, myalgia and seldom meningismus and pulmonary edema. To test the hypothesis that this OKT3 induced reaction relates to in vivo cell activation leading to bulk release of cytokines in the circulation, 35 renal allograft recipients receiving OKT3 were studied. Blood samples were collected before and at one and four hours following the first, second and third OKT3 injections. Results showed that the first injection induces a sharp increase in circulating tumor necrosis factor (TNFa) and interferon gamma (INF7) levels peaking respectively one hour and four hours after the OKT3 injection. IL-2 peaking four hours after the injection was detected only in the sera of three patients who did not receive steroids. Serum cytokine levels were back to pretreatment values by 15 to 20
hours. This cytokine release fully confirms the anti-CD3 in vivo induced cell activation and parallels the clinical reaction that is as cytokine release self-limited. Although not lethal in most instances, this reaction is highly disabling to the patients and has up to now prevented the extension of its use to clinical settings other than transplantation. To get further insights into the pathophysiology of the reaction and to test different therapeutic strategies trying to circumvent it, a murine model using the 145 2C1 I MoAb that is a hamster anti-murine CD3 MoAb was set up. Mice receiving this MoAb presented, like human patients, both a severe physical reaction associating hypomotility, hypothermia, diarrhea and piloerection, and paralleling this disease a bulk release of several cytokines (mainly TNF, IL-2, IFN7, IL-3 and IL-6) detected in sera drawn 90 minutes, 4, 8 and 24 hours after OKT3 injection. Importantly, severe anatomopathological lesions affecting lungs and liver were also obvious 24 hours after the injection. Different mouse strains, NZW, C3H/HeJ and CBAIJ, receiving the same anti-CD3 dose reacted differently. These data are in keeping with a different pattern of cytokine release and points to the importance of synergisms existing among these cytokines and to the pivotal role played by some of these molecules, but not all, in the induction of the disease (TNF, IFNy). Interesting and promising results indicating the beneficial effect of anti-TNF MoAb in the prevention of the OKT3-induced reaction were presented.
T. Strom (Boston) presented an alternative approach using IL-2-toxin conjugate. This conjugate induces selective depletion and impairment of activated T cells that express a high level of the IL-2 receptor. It is not toxic, and shows higher activity than anti-IL-2 receptor antibodies. It has been successfully applied in the prevention of heart allograft rejection and autoimmunity in lupus and diabetic mice.
